Bristol-Myers Squibb (BMY) and lung health company Optellum are collaborating to boost early lung cancer diagnosis using artificial intelligence, Optellum said Tuesday.
Under the companies' agreement, Optellum will use its Virtual Nodule Clinic platform at various US health care systems to democratize access to early diagnosis and to evaluate the platform's real-world impact before and after implementation, Optellum said.
The company said the deployments of the platform aim to generate and promote evidence and AI implementation best practices, helping accelerate AI-powered early diagnosis.
Price: 50.30, Change: -1.04, Percent Change: -2.03
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.